Cyclin-Dependent Kinase 4/6 Inhibitors as Neoadjuvant Therapy of Hormone Receptor-Positive/HER2-Negative Early Breast Cancer: What do we Know so Far?
Clinical Breast Cancer · 2024
DOI: 10.1016/j.clbc.2024.01.002 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Breast Cancer, 2024. Verfasst von Ioanna Ploumaki und 6 weiteren Autor:innen. Beteiligte Einrichtung: Oncology Unit, 3rd Department of Medicine, Sotiria General Hospital, National and Kapodistrian University of Athens, Αthens, Greece. Electronic addre…. Hauptthemen laut MEDLINE: Breast Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 54 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Oncology Unit, 3rd Department of Medicine, Sotiria General Hospital, National and Kapodistrian University of Athens, Αthens, Greece. Electronic address: ioannaploum@gmail.com.
- Oncology Unit, 3rd Department of Medicine, Sotiria General Hospital, National and Kapodistrian University of Athens, Αthens, Greece.
Zitieren
APA
Ploumaki, I., Triantafyllou, E., Koumprentziotis, I. A., Karampinos, K., Drougkas, K., Karavolias, I., & Kotteas, E. (2024). Cyclin-Dependent Kinase 4/6 Inhibitors as Neoadjuvant Therapy of Hormone Receptor-Positive/HER2-Negative Early Breast Cancer: What do we Know so Far?. Clinical Breast Cancer. https://doi.org/10.1016/j.clbc.2024.01.002
Vancouver
Ploumaki I, Triantafyllou E, Koumprentziotis IA, Karampinos K, Drougkas K, Karavolias I, et al. Cyclin-Dependent Kinase 4/6 Inhibitors as Neoadjuvant Therapy of Hormone Receptor-Positive/HER2-Negative Early Breast Cancer: What do we Know so Far?. Clinical Breast Cancer. 2024. doi:10.1016/j.clbc.2024.01.002
BibTeX
@article{Ploumaki2024,
author = {Ploumaki, Ioanna and Triantafyllou, Efthymios and Koumprentziotis, Ioannis-Alexios and Karampinos, Konstantinos and Drougkas, Konstantinos and Karavolias, Ioannis and Kotteas, Elias},
title = {Cyclin-Dependent Kinase 4/6 Inhibitors as Neoadjuvant Therapy of Hormone Receptor-Positive/HER2-Negative Early Breast Cancer: What do we Know so Far?},
journal = {Clinical Breast Cancer},
year = {2024},
doi = {10.1016/j.clbc.2024.01.002}
}
EUVIMED